Hyperhomocysteinaemia and immune activation in patients with cancer

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 1, 2007, Pages 47-53

  Schroecksnadel, Katharina ^a,b   Frick, Barbara ^a,b   Fiegl, Michael ^c   Winkler, Christiana ^a,b   Denz, Hubert A ^c   Fuchs, Dietmar ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c Hospital Natters/Innsbruck   (Austria)

Author keywords

Cancer; Cysteine; Folate; Homocysteine; Inflammation; Neopterin; Vitamin B 12

Indexed keywords

C REACTIVE PROTEIN; CYANOCOBALAMIN; CYSTEINE; FOLIC ACID; HOMOCYSTEINE; NEOPTERIN;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; CANCER; CANCER MORTALITY; CANCER PATIENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEMALE GENITAL TRACT TUMOR; FOLIC ACID BLOOD LEVEL; GASTROINTESTINAL TUMOR; GYNECOLOGIC CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNE RESPONSE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR LOCALIZATION; VITAMIN BLOOD LEVEL; VITAMIN METABOLISM;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYSTEINE; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; IMMUNE SYSTEM; MALE; NEOPLASMS; NEOPTERIN; VITAMIN B 12;

EID: 33846539796     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2007.012     Document Type: Article

References (43)

1. Selhub J, Jacques PF, Rosenberg IH, Rogers G, Bowman BA, Gunter EW, et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999;131:331-9.
2. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995;274:1049-57.
3. McCully KS. Homocysteine and vascular disease. Nat Med 1996;2:386-9.
4. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407-13.
5. Wu LL, Wu JT. Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clin Chim Acta 2002;322:21-8.
6. Sun CF, Haven TR, Wu TL, Tsao KC, Wu JT. Serum total homocysteine increases with the rapid proliferation rate of tumor cells and decline upon cell death: a potential new tumor marker. Clin Chim Acta 2002;321:55-62.
7. Rampersaud GC, Bailey LB, Kauwell GP. Relationship of folate to colorectal and cervical cancer: review and recommendations for practitioners. J Am Diet Assoc 2002;102:1273-82.
8. 12, homocysteine, and risk of breast cancer. J Natl Cancer Inst 2003;95:373-80.
9. Zhang SM, Willett WC, Selhub J, Manson JE, Colditz GA, Hankinson SE. A prospective study of plasma total cysteine and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1188-93.
10. Prinz-Langenohl R, Fohr I, Pietrzik K. Beneficial role for folate in the prevention of colorectal and breast cancer. Eur J Nutr 2001;40:98-105.
11. Storz P. Reactive oxygen species in tumor progression. Front Biosci 2005;10:1881-96.
12. Nathan CF. Peroxide and pteridine: a hypothesis on the regulation of macrophage antimicrobial activity by interferon γ. Interferon 1986;7:125-43.
13. Murr C, Fuith LC, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anti-cancer Res 1999;19:1721-8.
14. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 2004;6:297-305.
15. Chern CL, Huang RF, Chen YH, Cheng JT, Liu TZ. Folate deficiency-induced oxidative stress and apoptosis are mediated via homocysteine-dependent overproduction of hydrogen peroxide and enhanced activation of NF-κB in human Hep G2 cells. Biomed Pharmacother 2001;55:434-42.
16. Odin E, Carlsson G, Frosing R, Gustavsson B, Spears CP, Larsson PA. Chemical stability and human plasma pharmacokinetics of reduced folates. Cancer Invest 1998;16:447-55.
17. Fuchs D, Jaeger M, Widner B, Wirleitner B, Artner-Dworzak E, Leblhuber F. Is hyperhomocysteinemia due to the oxidative depletion of folate rather than to insufficient dietary intake? Clin Chem Lab Med 2001;39:691-4.
18. Reibnegger G, Fuchs D, Fuith LC, Hausen A, Werner ER, Werner-Felmayer G, et al. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev 1991;15:483-90.
19. Hronek M, Zadak Z, Solichova D, Jandik P, Melichar B. The association between specific nutritional antioxidants and manifestation of colorectal cancer. Nutrition 2000;16:189-91.
20. Frick B, Rudzite V, Schroecksnadel K, Kalnins U, Erglis A, Trusinskis K, et al. Homocysteine, B vitamins and immune activation in coronary heart disease. Pteridines 2003;14:82-7.
21. Schroecksnadel K, Leblhuber F, Frick B, Wirleitner B, Fuchs D. Association of hyperhomocysteinemia in Alzheimer disease with elevated neopterin levels. Alzheimer Dis Assoc Disord 2004;18:129-33.
22. Schroecksnadel K, Frick B, Wirleitner B, Winkler C, Schennach H, Fuchs D. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 2004;5:107-18.
23. Schroecksnadel K, Frick B, Wirleitner B, Schennach H, Fuchs D. Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells. Clin Exp Immunol 2003;134:53-6.
24. Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem 2004;37:684-7.
25. Frick B, Schroecksnadel K, Neurauter G, Wirleitner B, Artner-Dworzak E, Fuchs D. Rapid measurement of total plasma homocysteine by HPLC. Clin Chim Acta 2003;331:19-23.
26. Almadori G, Bussu F, Galli J, Cadoni G, Zappacosta B, Persichilli S, et al. Serum folate and homocysteine levels in head and neck squamous cell carcinoma. Cancer 2002;94:1006-11.
27. Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991;51:828-35.
28. Piyathilake CJ, Johanning GL, Macaluso M, Whiteside M, Oelschlager DK, Heimburger DC, et al. Localized folate and vitamin B-12 deficiency in squamous cell lung cancer is associated with global DNA hypomethylation. Nutr Cancer 2000;37:99-107.
29. Fuith LC, Artner-Dworzak E, Daxenbichler G. Tumor markers in gynecology. Wien Klin Wochenschr 1989;101:489-91.
30. Reibnegger G, Hetzel H, Fuchs D, Fuith LC, Hausen A, Werner ER, et al. Clinical significance of neopterin for prognosis and follow-up in ovarian cancer. Cancer Res 1987;47:4977-81.
31. Reibnegger GJ, Bichler AH, Dapunt O, Fuchs DN, Fuith LC, Hausen A, et al. Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res 1986;46:950-5.
32. Murr C, Bergant A, Widschwendter M, Heim K, Schrocksnadel H, Fuchs D. Neopterin is an independent prognostic variable in females with breast cancer. Clin Chem 1999;45:1998-2004.
33. Lewenhaupt A, Ekman P, Eneroth P, Eriksson A, Nilsson B, Nordstrom L. Serum levels of neopterin as related to the prognosis of human prostatic carcinoma. Eur Urol 1986;12:422-5.
34. Weiss G, Kronberger P, Conrad F, Bodner E, Wachter H, Reibnegger G. Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res 1993;53:260-5.
35. Kronberger P, Weiss G, Tschmelitsch J, Fuchs D, Salzer GM, Wachter H, et al. Predictive value of urinary neopterin in patients with lung cancer. Eur J Clin Chem Clin Biochem 1995;33:831-7.
36. Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T. Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 2003;238:197-202.
37. de Mello J, Struthers L, Turner R, Cooper EH, Giles GR. Multivariate analyses as aids to diagnosis and assessment of prognosis in gastrointestinal cancer. Br J Cancer 1983;48:341-8.
38. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998;176:335-8.
39. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, et al. Soluble receptor activator of nuclear factor κB ligand- osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003;102:1064-9.
40. 12 and transcobalamin abnormalities in patients with cancer. Cancer 1977;40:1348-53.
41. Cortelezzi A, Fracchiolla NS, Bamonti-Catena F, Motta M, Cighetti G, Carrabba M, et al. Hyperhomocysteinemia in myelodysplastic syndromes: specific association with autoimmunity and cardiovascular disease. Leuk Lymphoma 2001;41:147-50.
42. Schroecksnadel K, Frick B, Kaser S, Wirleitner B, Ledochowski M, Mur E, et al. Moderate hyperhomocysteinaemia and immune activation in patients with rheumatoid arthritis. Clin Chim Acta 2003;338:157-64.
43. Frick B, Neurauter G, Diez-Ruiz A, Schroecksnadel K, Wirleitner B, Leblhuber F, et al. Neopterin and oxidation products in the blood of patients with various forms of dementia. Pteridines 2003;13:88-93.